Although many of these patients are still young, a large number would have been expected to have developed schwannomas if the risks were similar to typical LZTR1 loss-of-function variants, since the median age at onset in people with a pathogenic LZTR1 variant is 38 years in our cohort and 20% developed symptomatic tumors below the age of 29 (~85% of the 22q11.2DS cohort is below this age). Here, LZTR1 is linked to schwannoma.